To access this element change to forms mode OFF
Grant Award View - GA166509
Employing rational novel agent combination therapy to improve transplant...
GA ID:
GA166509
Agency:
Department of Health and Aged Care
Approval Date:
17-Apr-2021
Publish Date:
25-May-2021
Category:
Health and Medical Research
Grant Term:
1-Jun-2021 to 31-May-2025
Value (AUD):
$1,225,487.40
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_RCRDUN_RCRDUN_2021_General
Grant Activity:
Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma
Purpose:
Hodgkin Lymphoma (HL) is a rare malignancy, with 500 new cases annually in young Australians. While 70 percent of patients are cured with front line treatment, 30 percent of patients require second line therapy which often fails resulting in death. Immunotherapy and targeted therapies have dramatically improved survival in haematological malignancies. This study will combine two agents currently approved in recurrent HL the second line setting, earlier to maximise survival of these young Australians.
GO ID:
GO Title:
MRFF Clinical Trials Activity Initiative – 2020 Rare Cancers, Rare Diseases and Unmet Need General Grant Opportunity
Internal Reference ID:
MRF2006108
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
La Trobe University
Recipient ABN:
64 804 735 113
Grant Recipient Location
Suburb:
Bundoora
Town/City:
Bundoora
Postcode:
3083
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, WA, QLD, TAS, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, CANADA